Fredrik Lindberg is appointed as the new CEO of Moroxite AB

The Board of Directors of Moroxite AB has appointed Fredrik Lindberg as the new CEO, and he will start May 5, 2025. 

Fredrik Lindberg MD, PhD brings with him an extensive experience in pharma, life science and MedTech. He comes most recently from the position as CEO of AGB-Pharma AB. Fredrik has previously held positions as Head at the Department of Clinical Pharmacology, Lund University Hospital, Nordic Medical Director at Searle Pharmaceuticals, Co-founder and CEO of Bone Support AB, and CEO of Enzymatica AB. 

"It will be extremely exciting to continue to build Moroxite AB, a research company at the forefront of developing next generation therapeutics in spinal fusion and osteoporotic fracture fixation. Spinal fusion surgery is a critical intervention for degenerative spinal conditions, affecting millions worldwide. Existing methods, reliant on autograft (patient’s own bone) are invasive, resource-intensive, and have high failure rates. Moroxite AB addresses this need with XerafuseTM BMP, a next-generation Orthobiologic bone substitute that will revolutionize spinal fusion through advanced biomaterial design and controlled drug delivery”. Fredrik Lindberg, CEO Moroxite AB. 

“I look forward with great confidence that Fredrik Lindberg, together with employees and partners, will take the company's ceramic platform with proprietary bone active protein to regulatory approval and market introduction." Semmy Rülf, Chairman of the Board Moroxite AB.

Moroxite AB is dedicated to the development of next generation therapeutics in spinal fusion and fracture fixation. We aim to improve patient quality of life and cut societal cost by eliminating the need for autograft in spinal fusion and decrease surgery associated failure rates.